PIN1 and cancer: To this end, we used Sulfopin, a recently identified covalent Pin1-specific inhibitor that targets the functionally critically Cys113 and the ATO-binding pocket in the Pin1 catalytic active site and effectively inhibits Pin1 function in cancer in vitro and in vivo73,74.